Patients should have no pathological findings in their breasts on preoperative screening. There should be no active disease, such as inflammation, infection or tumours in or near the intended treatment site.
Patients with a history of breast cancer or pre-cancerous breast lesions and patients assessed to have a higher risk for developing breast or ovarian cancer have not been studied.
Furthermore, patients need to have realistic expectations about the results that can be achieved; they should also have sufficient tissue cover and no pronounced ptotic (sagging) breasts.
Patients with bleeding disorders or patients who are taking thrombolytics or anticoagulants should not be treated. Patients who are using substances that affect platelet functions, such as aspirin and non-steroidal anti-inflammatory drugs may, as with any injection, experience increased bruising or bleeding at injection sites.
Surgical and trauma scars involving more pronounced fibrosis should be treated with caution as the scars may need release of fibrous bands. Markedly indurated defects may be difficult to treat.
Do not use in patients who have experienced delayed inflammatory reactions or implant complications in connection with previous NASHA treatments and have required further medical treatment.
There is no data on the use of Macrolane in children or pregnant or lactating women.
For further information please refer to the instructions for use.